%0 Journal Article %A Satu Strausz %A Tuomo Kiiskinen %A Martin Broberg %A Sanni E. Ruotsalainen %A Jukka Koskela %A Adel Bachour %A FinnGen %A Aarno Palotie %A Tuula Palotie %A Samuli Ripatti %A Hanna M. Ollila %T Sleep apnoea is a risk factor for severe COVID-19 %D 2020 %R 10.1101/2020.09.26.20202051 %J medRxiv %P 2020.09.26.20202051 %X Objective To investigate if obstructive sleep apnoea (OSA) is an independent risk factor for severe COVID-19. To examine whether the risk for contracting COVID-19 is elevated among OSA patients.Design and setting Registry based retrospective case-control study using Finnish nationwide health registries and the FinnGen Study cohort.Participants Information regarding OSA diagnosis and COVID-19 infection was extracted from the FinnGen study (N=260,405) with a total of 305 patients who had a recorded PCR-validated COVID-19 infection including 26 (8.5%) individuals who were also OSA patients. Severe COVID-19 (N=83; 27.2%) was defined as an infection requiring hospitalization. Among the hospitalized individuals there were 16 (19.3%) with OSA diagnosis. In addition, we also included in our analysis previously reported risk factors for both severe COVID-19 or risk factors and comorbidities for OSA from FinnGen.Main outcome measures OSA diagnosis, information concerning COVID-19 infection such as hospitalization, were derived from Finnish National Hospital Discharge Registry, Causes of Death Registry and the National Infectious Diseases Registry.Results We show that OSA is a risk factor for COVID-19 hospitalization independent from age, sex, body mass index (BMI), hypertension, diabetes, coronary heart disease (CHD), asthma and chronic obstructive pulmonary disease (COPD), (p-unadjusted=1.04×10−4, OR-adjusted=5.24 [95%CI 1.33 to 23.43], p-adjusted=0.022). OSA was not associated with the risk of contracting COVID-19 (p=0.49).Conclusion While an OSA patient’s risk of contracting COVID-19 is the same as non-OSA individuals, the OSA patients have a five-fold risk to be hospitalized when affected by COVID-19 than non-OSA individuals. Our findings suggest that, in assessment of patients with suspected or confirmed COVID-19 infection, OSA needs to be recognized as one of the comorbidity risk factors for developing a severe form of the disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSR was supported by the Academy of Finland Center of Excellence in Complex Disease Genetics (Grant No 312062), the Finnish Foundation for Cardiovascular Research, the Sigrid Juselius Foundation and University of Helsinki HiLIFE Fellow and Grand Challenge grants and Juho Vainio Foundation & Academy of Finland Covid-19 research funding. AP was supported by the Academy of Finland Center of Excellence in Complex Disease Genetics (Grant No 312074), and the Sigrid Juselius Foundation). HMO was supported by the Academy of Finland [Grant No 309643], Oskar Offlund foundation and Yrjo Jahnsson foundation and TP by the HUCH research grant. The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Celgene Corporation, Celgene International II Sarl, Genentech Inc., Merck Sharp & Dohme Corp, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc. Following biobanks are acknowledged for the project samples: Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-US/Research_and_development/Finnish_Clinical_Biobank_Tampere), Biobank of Eastern Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta) and Terveystalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). All Finnish Biobanks are members of BBMRI.fi infrastructure (www. bbmri.fi). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Review Board of the Hospital District of Helsinki and Uusimaa approved the FinnGen study protocol (HUS/990/2017).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe FinnGen data may be accessed through Finnish Biobanks FinnBB portal (www.finbb.fi) and THL Biobank data may be accessed through THL Biobank (https://thl.fi/en/web/thl-biobank). %U https://www.medrxiv.org/content/medrxiv/early/2020/09/28/2020.09.26.20202051.full.pdf